Novo Nordisk, the Danish drugmaker behind Wegovy and Ozempic, will use Anthropic’s Claude models to accelerate drug discovery and development, the two companies said Wednesday.
The Big Picture
- Novo Nordisk will test Anthropic’s frontier models and Claude Science across its research and development workflows starting now.
- The companies will target scientific problems where their combined capabilities offer the biggest impact first.
- Novo already uses Claude to automate trial report generation, cutting patient documentation timelines from months to minutes.
- CEO Mike Doustdar says AI can help researchers understand human biology and drug mechanics beyond current use cases.
- Novo will also apply Anthropic’s models to strengthen its own AI-driven software development.
Novo taps Claude for R&D and software
Novo Nordisk will initially test Anthropic’s models and Claude Science in its research and development workflows, addressing scientific problems where their joint capabilities can have the greatest impact, the companies said.
Novo CEO Mike Doustdar said:
The Wegovy maker will also apply Anthropic’s frontier models to strengthen its internal software development, extending the partnership past drug discovery into its broader technology stack. The new deal builds on a working track record, since Novo already uses Claude to trim patient documentation timelines from months to minutes.
Novo says it wants to become the world’s most AI-driven healthcare company, framing AI as a way to raise R&D productivity and shorten the path to market. The company employs more than 67,000 people globally and says the collaboration includes data governance and human oversight aligned with its existing compliance standards.
Behind every scientific breakthrough is a person waiting for it – a patient, a family, a caregiver hoping for better treatment options.
— Novo Nordisk (@novonordisk) September 16, 2026
We are therefore excited to announce a new partnership with @AnthropicAI, so our scientists, by the use of AI, can bring new medicines to the… pic.twitter.com/na7FEGDVBn
Drugmakers widen the AI bet
Novo’s move lands inside a broader pharmaceutical shift, as drugmakers increasingly turn to AI to accelerate R&D and improve efficiency across their pipelines. The deal adds a healthcare name to a growing list of Anthropic’s enterprise partnerships across other industries.
Anthropic CEO Dario Amodei framed the deal as a bet on compounding capability gains. Amodei said:
Implications for AI in pharma
A deal with one of the world’s largest insulin and GLP-1 manufacturers gives Anthropic a marquee reference customer in life sciences, a sector where AI vendors compete heavily for credibility with regulators. Novo’s existing use of Claude for trial documentation suggests the R&D expansion could follow the same pattern: narrow, workflow-specific deployments that scale once they show measurable time savings. The approach arrives as AI industry leaders remain split over how fast the technology should advance, and Novo’s emphasis on governance signals an intent to move quickly while keeping compliance teams satisfied.
Why It Matters?
This partnership formalizes something Novo was already doing quietly. Its use of Claude to compress trial documentation from months to minutes gave both sides a proof point before committing to a broader research relationship, which is why the announcement reads as an expansion, not a pilot. Anthropic gets a healthcare reference deal with a manufacturer whose drugs reach millions of patients, while Novo gets a vendor it can cite when explaining its AI governance choices to regulators.
What comes next depends on how fast the two companies identify the “scientific problems where their joint capabilities can have the greatest impact,” language both used in the announcement. Expect early disclosures to focus on narrow R&D workflows, not end-to-end drug discovery claims, since Novo ties the work to human oversight, not autonomous research.
